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METHODOLOGY Open Access
Ultra-high field MR angiography in human
migraine models: a 3.0 T/7.0 T comparison
study
Casper Emil Christensen1, Samaira Younis1, Ulrich Lindberg2, Vincent Oltman Boer3, Patrick de Koning4,
Esben Thade Petersen3,5, Olaf Bjarne Paulson6, Henrik Bo Wiberg Larsson2, Faisal Mohammad Amin1† and
Messoud Ashina1*†
Abstract
Background: Sildenafil and calcitonin gene-related peptide both dilate the intradural segments of the middle
meningeal artery measured with 3.0 tesla (T) MR angiography. Here we hypothesized that an increase in field
strength to 7.0 T and concomitant enhanced voxel resolution would lower variance in measurements of dilation in
the intradural middle meningeal artery.
Methods: Five subjects completed two sessions at respectively 3.0 T and 7.0 T. Each session comprised MR
angiography scans once before and twice after administration of sildenafil, calcitonin gene-related peptide or
placebo in a three-way, crossover, double-blind, placebo-controlled design.
Results: Standard deviations of arterial circumference revealed no difference between 3.0 T and 7.0 T
measurements (p = 0.379). We found a decrease in standard deviation from our original angiography analysis
software (QMra) to a newer (LAVA) software package (p < 0.001). Furthermore, we found that the dilation after
sildenafil and calcitonin gene-related peptide were comparable between 3.0 T and 7.0 T.
Conclusions: Our findings suggest no gain from the increase in voxel resolution but cemented dilatory findings
from earlier. The implemented software update improved variance in circumference measurements in the intradural
middle meningeal artery, which should be exploited in future studies.
Trial registration: The study is part of a parent study, which is registered at ClinicalTrials.gov (NCT03143465).
Keywords: Middle meningeal artery, Dura mater, Neurovascular, Sildenafil, Calcitonin gene-related peptide
Background
Neurovascular mechanisms of migraine headache has
been studied extensively using magnetic resonance angi-
ography (MRA) [1–5]. The middle meningeal artery
(MMA) is an essential focus of these studies, both in
search for the origin of pain and as a physiological meas-
ure of altered neurovascular modulation [6]. Two MRA
studies found the extracranial part of MMA to be dilated
more on the pain side than non-pain side in migraine
patients during provoked attacks in human migraine
models [1, 4]. If MMA dilation reflects activation of
trigeminal nociceptors and meningeal neuropeptide
release, then the intracranial segments of MMA might
represent more local changes in the dural environment
than the extracranial part.
In an effort to study dilation in the intracranial segments
of the MMA, we recently performed a 3.0 tesla (T) MRA
study in healthy volunteers showing dilation of the intra-
dural MMA after administration of headache-inducing
substances calcitonin gene-related peptide (CGRP) and
sildenafil [7]. Changes in MMA dimensions within sub-
jects over time in previous MRA studies vary from ~ 30%
[3] to as little as ~ 5% [4] which challenges detection rate
and power in costly and time-consuming MRI studies.
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Furthermore, the route of the MMA in the cranial
convexity potentially limits the cross-sectional MRA reso-
lution [8].
In this study, we wanted to investigate whether the un-
certainty – defined as standard deviation (SD) of mea-
surements along the course of the intradural MMA –
improves when increasing the field strength from 3.0 T
to 7.0 T, potentially increasing spatial resolution and
diminishing the partial volume effect. We used a ran-
domized, placebo-controlled, three-way, crossover,
double-dummy setup at 7.0 T in participants who had
previously gone through the exact same setup at 3.0 T
and we compared standard deviations in measurements
between the two systems.
Methods
Participants and approvals
We recruited healthy volunteers through a Danish
recruitment website (www.forsoegsperson.dk). Partici-
pants were offered enrollment in this 7.0 T continuation
study upon completion of the prior 3.0 T study, results
of which have been published elsewhere [7]. Both men
and women were eligible for inclusion if they were be-
tween 18 and 50 years of age, weighed 50 to 100 kg and
had successfully completed the 3.0 T part of the parent
study. Exclusion criteria were a history of somatic and/
or psychiatric disease any primary headache disorder,
other than infrequent episodes of tension type headache
(less than 2 days/month), having first-degree relatives
with migraine, being pregnant or breastfeeding, use of
daily medication, other than oral contraceptives and not
using safe contraceptive methods. Furthermore, volun-
teers were excluded if there were contraindications for
MRI scans (i.e. ferromagnetic implants, recent surgical
procedures, claustrophobia, etc.) or any other condition
deemed by the investigator to be incompatible with
participation. Participants provided written informed
consent in accordance with the declaration of Helsinki
and the study was approved by the Ethics committee of
the Capital Region of Denmark (H-15019063) along with
the Danish Medicines Agency (CIV-16-12-017964). The
study is part of a parent study, which is registered at
ClinicalTrials.gov (NCT03143465) and other parts of the
study have been or will be published elsewhere.
Study design
Participants were allocated to receive CGRP, sildenafil
and placebo in random order on three separate study
days. Drug administration was preceded by a 7.0 T MRA
and succeeded by two additional scans at 30 min and
120 min post-administration. On each day, participants
would receive an i.v. infusion of isotonic saline or CGRP
as well as an oral administration of 100 mg sildenafil or
placebo, where the combination was dependent on
randomization (placebo+CGRP/sildenafil+placebo/pla-
cebo+placebo). This design was a replica of the previous
3.0 T study which all participants had previously com-
pleted at Rigshospitalet Glostrup, resulting in paired ob-
servations between 3.0 T and 7.0 T.
Experimental procedures
Participants arrived at the Danish Research Centre for
Magnetic Resonance headache-free on the morning of
each study day. They were required to avoid intake of any
medication (other than oral contraceptives), coffee, tea,
cocoa, other caffeinated beverages and methylxanthine-
containing food 12 h before the first scan and to fast 4 h
before commencing the experiment. After arrival, a per-
ipheral venous catheter was placed in a cubital vein and
participants were placed in the scanner. They were
instructed to stay awake during the recordings.
MR angiography scans were obtained at baseline (TBa-
seline) followed by drug administration at T0 and two
additional MRI scans at T30 and T120. Participants were
monitored with an Expression In Vivo monitor (Philips
Medical, Orlando, FL, USA) continuously, regarding
blood pressure, heart rate, end-tidal CO2, respiratory
rate and pulse oximetry every 10 min following drug
administration. A standardized headache questionnaire
was used to evaluate any headache-related symptoms for
the duration of the study where pain was scored on a
numerical rating scale (NRS) from 0 (no pain) to 10
(maximum imaginable pain).
Data acquisition
The acquisition of the 3.0 T scans used for comparisons in
this study are described in detail elsewhere [7]. The 3.0 T
MRI scans were performed on a Philips Achieva dStream
Scanner (Philips Medical Systems, Netherlands) using a
32-channel phased-array head coil. A three-dimensional
time-of-flight (TOF) MRA was conducted with the follow-
ing parameters:
Field of view 200 × 200 × 36.75 mm3, acquired matrix
size 800 × 570, acquired voxel resolution 0.25 × 0.35 ×
0.70 mm3, reconstructed voxel resolution 0.20 × 0.20 ×
0.35 mm3, TR 23 milliseconds, TE 3.5 milliseconds, flip
angle 18°, SENSE p reduction 2.5, 3 chunks, duration 13
min 06 s.
The 7.0 T MRI scans were performed on a 7.0 T Phi-
lips Achieva Scanner (Philips Medical Systems,
Netherlands) using a two-channel volume transmit head
coil with 32-channel receiver array (Nova Medical, Inc.,
Burlington, MA, US). Again, a three-dimensional TOF
MRA sequence was used with the following parameters:
Field of view 200 × 190.4 × 32.4 mm3, acquired matrix
size 668 × 636, acquired voxel resolution 0.3 × 0.3 × 0.3
mm3, reconstructed voxel resolution 0.15 × 0.15 × 0.15
mm3, TR 19 milliseconds, TE 2.6 milliseconds, flip angle
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30°, SENSE p reduction 4.5, 3 chunks, duration 9 min
58 s.
High-dielectric permittivity pads were placed over the
temporomandibular joint to improve image quality at
the base of the skull, where intradural segments of the
MMA is located [9].
Data analysis
MR angiography data was transferred to a separate work
station in the DICOM format and analyzed using LKEB
QMra, and the updated LKEB LAVA vessel contour
detection software [10, 11]. The software allows the user
to pinpoint start- and endpoint of vessels for contour
analysis, propagates a center line through the vessel and
provides circumference slices perpendicular to this line
along the chosen segment. If slices were distorted, noisy
or otherwise immeasurable, they were discarded. The
user made sure to select the same segments within each
subject between scans to provide reliable measurements
of change over time. We analyzed the intradural seg-
ment of MMA, identified as the innermost part covered
by the field of view, approximately 20 mm after MMA
enters the skull through the foramen spinosum. Ultim-
ately, a 5 mm segment is chosen comprising up to 34
slices and the mean and standard deviation is computed
for that segment at that time point. 7.0 T MRA reso-
lution required us to use updated contour detection soft-
ware (LAVA), which was not used in the original study,
causing us to reanalyze the previous data using the new
software post hoc. To further explore the potential effect
of the resolution on 7.0 T, we resampled the 7.0 T data,
decreasing the resolution, to mimic the original 3.0 T
scans. Both QMra and LAVA analyses are reported, and
the software change was factored into analyses (see
below). All analyses of 3.0 T and 7.0 T scans were
performed on the same workstation by CEC.
Statistical analyses
Our primary endpoint was difference in SDs of vessel
segment measurements in intradural MMA at 3.0 T vs.
7.0 T within subject, within drug, within time point pro-
viding us with a maximum of 5subjects x 3days x 3times x
2sides = 90 paired observations. Vessel segment standard
deviation was analyzed with a linear mixed effects model
with scanner and contour detection software as fixed ef-
fects and subject, drug and time point as random effects.
Secondary analyses on drug effect on circumference over
time were performed descriptively as percentage change
from baseline and using Bland-Altman agreement statis-
tics between scanners [12].
All analyses were performed using R (version 3.4.2)
with packages lme4 (version 1.1–17) and BlandAltmann-
Leh (version 0.3.1), p-values are reported as two-tailed
with a significance level of 5%.
Results
Five participants who had completed the 3.0 T parent
study went on to complete the 7.0 T extension. Two
men and three women mean age 24 (range 20 to 29).
The median number of days between 3.0 T and 7.0 T
studies were 476 (range 330 to 501).
Mean SD for intradural MMA on 3.0 T with QMra soft-
ware was 0.332mm (SE 0.033), mean circumference was
4.18mm (95% CI [4.04 to 4.32]). We found no difference
Fig. 1 Standard deviations of the intradural MMA measurements in the four analysis iterations. 7.0 T High Res: 7.0 T scan at full resolution; 7.0 T
Low Res: 7.0 T scan resampled to 3.0 T resolution
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in SD between 3.0 T and 7.0 T when applying the same
LAVA software on both (p = 0.379), but SD was 0.184mm
lower for LAVA than for QMra independent of scanner
field strength (p < 0.001). We found no difference between
resampled and original 7.0 T standard deviations (Fig. 1).
Arterial circumference change over time between the
two scanners are shown in Fig. 2. We found similar
patterns across the three interventions with immediate
increase in arterial circumference both after CGRP
(15.8% at 3.0 T and 23.5% at 7.0 T) and sildenafil (7.6%
at 3.0 T and 12.1% at 7.0 T). Dilation after sildenafil
appears to be sustained after 120 min (21.0% at 3.0 T and
14.8% at 7.0 T) contrary to the CGRP-induced dilation
(Fig. 2). Correspondingly, Fig. 3 shows relatively high
levels of agreement between circumference measurements
at 3.0 T and 7.0 T within subject, drug and time (Fig. 3).
Examples of the different angiography recordings are
shown in Fig. 4. We observed an apparent decrease in
mean arterial pressure after sildenafil (Fig. 5) and a small
increase in heart rate after CGRP (not shown).
Discussion
The main outcome of this study was that we found no
difference in standard deviation of measurements of
Fig. 2 Change in intradural MMA circumference over time after each of the three interventions. 3.0 T and 7.0 T data is depicted as mean ± SE, all
data analyzed with LAVA software
Fig. 3 Bland-Altmann plot depicting agreement between circumference measurements of intradural MMA 3.0 T vs 7.0 T within subject, within
drug, within time point analyzed with LAVA software. Each point represents difference in circumference between 3.0 T and 7.0 T as a function of
mean of the two measurements. Dashed lines are overall mean of differences ±2SD
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intradural MMA circumference between 3.0 T and 7.0 T.
We did, however, uncover a difference in standard devi-
ation between the previously used QMra circumference
detection software and the newer LAVA. Furthermore,
we showed high robustness in measurements of vascular
effects of CGRP and sildenafil over time as the temporal
evolution from drug administration was similar between
the 3.0 and 7.0 T scan days (Fig. 2).
Sildenafil is a selective phosphodiesterase-5 inhibitor
that impedes degradation of cyclic guanosine monopho-
sphate (cGMP) which ultimately leads to relaxation of
vascular smooth muscle cells. [13] Calcitonin
gene-related peptide relaxes vascular smooth muscle via
a G-protein coupled receptor-mediated increase in cyclic
adenosine monophosphate (cAMP) [14]. We have previ-
ously shown the ability to measure intradural MMA cir-
cumference increase after either sildenafil or CGRP
using high resolution 3.0 T MRA [7]. The intradural
branches of the MMA move in all three planes and we
hypothesized, that we could improve confidence in our
caliber measurements, if we streamlined all dimensions
of the voxel size on MRA. In our previous study, the lowest
cross-sectional resolution was 0.35 × 0.70mm2, whereas at
7.0 T, we could increase the resolution to 0.3 × 0.3mm2.
However, this increase in resolution did not change the
standard deviations along the vessel segment measure-
ments. Neither did the temporal evolution of intradural
MMA caliber change, when moving to 7.0 T, showing
absolute robustness of our measurements from 3.0 T and
consolidating our previous findings (Figs. 2 and 3).
The contour detection software works by detecting a
pathline of the vessel chosen by the operator. Then a
model is fitted to the underlying image data defining a
3D mesh in non-uniform rational basis spline fashion
[11]. QMra software moves along the pathline and deter-
mines the best candidate in neighboring voxels as next
in line in the vessel contour [10]. The newer LAVA
program scans a wider range of potential voxels and
locates the best candidates using the maximum gradient
[11]. The older QMra software is thus more susceptible
to poor pathline estimations and noise whereas LAVA
looks at a broader range of voxels and is more resilient
to these effects.
In MRA research in migraine, changes in dimensions
of the MMA have been proposed a marker of meningeal
activation during migraine attacks, and changes reported
Fig. 4 Examples of the middle meningeal artery (arrow) in three different data sets. a: 3.0 T scan; b: 7.0 T scan at low resolution; c: 7.0 T scan at
high resolution
Fig. 5 Mean arterial blood pressure by time in the individual participants after each of the three interventions
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are as small as ~ 5% corresponding to around 0.15mm
in the intradural MMA circumference [4]. Needless to
say, a high level of confidence in measurements is
needed, and here we show robust MMA measurements
from our 3.0 T results even when re-testing at ultra-high
field strength.
Strengths and limitations
We tested standard deviations along vessel segments in
randomized, double-blind, placebo-controlled fashion
using the same subjects on the two different systems
resulting in quite strong paired comparisons. Further-
more, contour detection is a semi-automated procedure
with minimal operator influence [15]. A central limita-
tion is the time between 3.0 T and 7.0 T scans with a
median of 476 days between them.
Conclusions
We found no reduction in standard deviation with the
increase in voxel resolution from 3.0 T to 7.0 T. The
implemented software update, however, improved vari-
ance in circumference measurements in the intradural
MMA, which should be exploited in future studies. Fur-
thermore, we affirmed the dilatory response in intradural
MMA after sildenafil and CGRP that was reported previ-
ously [7].
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